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ABSTRACT The use of pathogen recognition receptor (PRR) agonists and the molec-
ular mechanisms involved have been the major focus of research in individual vac-
cine development. West Nile virus (WNV) nonstructural (NS) 4B-P38G mutant has
several features for an ideal vaccine candidate, including signiﬁcantly reduced neu-
roinvasiveness, induction of strong adaptive immunity, and protection of mice from
wild-type (WT) WNV infection. Here, we determined the role of mitochondrial antivi-
ral signaling protein (MAVS), the adaptor protein for RIG-I-like receptor in regulating
host immunity against the NS4B-P38G vaccine. We found that Mavs/ mice were
more susceptible to NS4B-P38G priming than WT mice. Mavs/ mice had a tran-
siently reduced production of antiviral cytokines and an impaired CD4 T cell re-
sponse in peripheral organs. However, antibody and CD8 T cell responses were
minimally affected. NS4B-P38G induced lower type I interferon (IFN), IFN-stimulating
gene, and proinﬂammatory cytokine responses in Mavs/ dendritic cells and subse-
quently compromised the antigen-presenting capacity for CD4 T cells. Interestingly,
Mavs/ mice surviving NS4B-P38G priming were all protected from a lethal WT
WNV challenge. NS4B-P38G-primed Mavs/ mice exhibited equivalent levels of pro-
tective CD4 T cell recall response, a modestly reduced WNV-speciﬁc IgM produc-
tion, but more robust CD8 T cell recall response. Taken together, our results sug-
gest that MAVS is essential for boosting optimal primary CD4 T cell responses
upon NS4B-P38G vaccination and yet is dispensable for host protection and recall T
cell responses during secondary WT WNV infection.
IMPORTANCE The production of innate cytokines induced by the recognition of
pathogen recognition receptors (PRRs) via their cognate ligands are critical for en-
hancing antigen-presenting cell functions and inﬂuencing T cell responses during
microbial infection. The use of PRR agonists and the underlying molecular mecha-
nisms have been the major focus in individual vaccine development. Here, we deter-
mined the role of mitochondrial antiviral-signaling protein (MAVS), the adaptor pro-
tein for RIG-I like receptor in regulating host immunity against the live attenuated
West Nile virus (WNV) vaccine strain, the nonstructural (NS) 4B-P38G mutant. We
found that MAVS is important for boosting optimal primary CD4 T cell response
during NS4B-P38G vaccination. However, MAVS is dispensable for memory T cell de-
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velopment and host protection during secondary wild-type WNV infection. Overall,
these results may be utilized as a paradigm to aid in the rational development of
other efﬁcacious live attenuated ﬂavivirus vaccines.
KEYWORDS MAVS, T cell, West Nile virus, adaptive immunity, T cells, vaccine
The production of innate cytokines induced by the recognition of pathogen recog-nition receptors (PRRs) via their cognate ligands is critical for enhancing antigen-
presenting cell (APC) functions and inﬂuencing T cell responses during microbial
infection (1–4). Thus, the involvement of PRR agonists and the molecular mechanisms
involved have been the major focus of research in individual vaccine development.
Flaviviruses, a group of single-stranded, positive-sense RNA viruses, contain several
pathogens of public health importance, including West Nile virus (WNV) and Zika virus
(ZIKV), for which we have no licensed vaccines. WNV has caused annual outbreaks of
acute viral encephalitis and neurological sequelae in North America since 1999. The
genome of WNV is about 11,000 nucleotides in length, which is translated and
processed into 10 proteins: three structural proteins (envelope [E], membrane, and
nucleocapsid) and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) (5). The NS4B protein of ﬂaviviruses is linked to evasion of host immune
responses and viral replication (6–8). The NS4B P38 residue is conserved among most
mosquito- and tick-borne ﬂaviviruses. An attenuating P38G substitution in the NS4B
protein was identiﬁed previously by site-directed mutagenesis of a WNV New York 1999
strain (NY99) infectious clone (9). Animal studies suggested that the WNV NS4B-P38G
mutant has multiple features of a vaccine candidate, including reduced neuroinvasive-
ness, induction of greater adaptive immune responses than wild-type (WT) WNV, and
protection of mice from subsequent lethal WT WNV infection (10). Nevertheless,
immune factors that contribute to development of strong adaptive immunity upon
WNV NS4B-P38G vaccination are not well described.
WNV infection activates several PRRs, including Toll-like receptors and RIG-I-like
receptors, which signal through adaptor molecules, such as TIR-domain-containing
adapter-inducing beta interferon (TRIF), myeloid differentiation factor 88 (MyD88), and
mitochondrial antiviral-signaling (MAVS; also known as IPS-1, VISA, or CARDIF). Signal-
ing through these adaptors ampliﬁes innate immune responses, culminating in the
synthesis of antiviral cytokines, including type I interferons (IFNs) and proinﬂammatory
cytokines (11–14). We have previously shown that MyD88 is required for induction of
proinﬂammatory cytokines, but not type I IFNs during NS4B-P38G infection in myeloid
dendritic cells (DCs). MyD88 deﬁciency also results in reduced primary and secondary
T cell responses (15). Here, we investigated the role of MAVS-dependent signaling
pathways in induction of innate and adaptive immune responses and host protection
by the NS4B-P38G vaccine. Our results suggest that MAVS is essential for primary CD4
T cell responses but dispensable for host protection and recall T cell responses during
secondary WNV infection.
RESULTS
MAVS is required for host survival after high-dose WNV NS4B-P38G priming.
We previously reported that WT B6 mice were highly resistant to WNV NS4B-P38G
infection. However, about 60% of NS4B-P38G-infected Myd88/ mice survived (15).
These results indicate that both MyD88-dependent and -independent immune signal-
ing pathways contribute to host defense against NS4B-P38G infection. MAVS, the
adaptor protein of RIG-I receptor is known to be important for host protection against
the pathogenic WT WNV (16). Here, we investigated the role of MAVS in regulating host
immunity against the NS4B-P38G vaccine strain. Initially, we infectedMavs/mice and
WT controls with a low dose (50 PFU) or a high dose (500 PFU) of WNV NS4B-P38G. All
Mavs/ mice succumbed to 500 PFU of WNV NS4B-P38G infection in less than 2
weeks. However, 50% of Mavs/ mice survived 50 PFU of NS4B P38G infection (Fig.
1A). All WT control mice infected with either the low or the high dose of WNV
Luo et al. Journal of Virology
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NS4B-P38G survived for at least 30 days without showing any clinical signs. Next, we
measured viral loads in organs of mice infected with 500 PFU of WNV NS4B-P38G.
Viremia was signiﬁcantly higher in Mavs/ mice compared to WT mice on days 2, 4,
and 6 as determined by focus-forming assay (FFA) and on days 4 and 6 as determined
by quantitative PCR (Q-PCR) assay (Fig. 1B and C). Viral loads in the spleen and brain
were also signiﬁcantly enhanced in Mavs/ mice compared to WT mice on days 4 and
6 (Fig. 1D and E). Spleens and brains were next collected from naive and infected mice
on days 4 and/or 7 for pathological examination (Fig. 1F and G). Tissue necrosis was not
observed in any section of the spleen in WNV NS4B-P38G-infected WT orMavs/mice.
Although there was apparent germinal-center proliferation in both groups compared
to noninfected mice, no differences were observed between the two groups. In the
central nervous system (CNS), we noted the presence of perivascular inﬁltrates with
mononuclear cells in the cerebral cortices and meninges, striata, cerebellar deep nuclei,
and brainstems of Mavs/ mice on day 7 postinfection (p.i.). In comparison, no
obvious inﬁltrates were observed in WT mice at any of these sites (Fig. 1G). Further-
more, we isolated brain leukocytes and examined their phenotype. On day 7, ﬂow
cytometry analysis indicated that the number of inﬁltrating macrophages (CD11bhi
CD45hi), CD4, and CD8 T cells in the brains of Mavs/ mice increased by 5- to
65-fold compared to those of WT control mice (Fig. 1H to J). Overall, these results
suggest that MAVS is essential for host protection during NS4B-P38G priming.
MAVS deﬁciency contributes to transiently reduced antiviral innate immune
responses in peripheral tissues of NS4B-P38G-vaccinated mice. MAVS is essential
for the induction of type I IFN and other innate antiviral responses during WT WNV
infection (14). Type I IFNs, including both IFN- and IFN-, participate in the direct
FIG 1 Mavs/ mice are susceptible to primary WNV NS4B-P38G mutant infection. (A) Survival of WT (n  20 or 17) and Mavs/ (n  44 or 17) mice after
i.p. injection with a low or high dose of WNV NS4B-P38G mutant. (B and C) Viral load in blood was determined by using a FFA (B) or a Q-PCR assay (C). (D and
E) Viral load in spleen (D) and brain (E) as determined by Q-PCR assay. Data are presented as means  the SEM (n  4 to 8). (F and G) Representative images
(20) shown are H&E-stained spleens (F) or brains (G) from NS4B-P38G-infected mice on day 4 (D4) and day 7 (D7) and/or noninfected (NF) WT and Mavs/
mice. Arrows were pointed to mononuclear inﬁltrates. (H to J) Brain leukocyte inﬁltration following WNV NS4B P38G mutant infection. The numbers of brain
leukocytes (H) or the percent positive brain leukocytes (I), including naive microglia cells (NMG), activated microglial cells (AMG), macrophages (M), and CD4
and CD8 T cells on day 7 p.i. were analyzed by ﬂow cytometry. Data are presented as means  the SEM (n  8 to 10 pooled from two experiments). *, P 
0.05; **, P  0.01 (compared to WT mice). (J) Representative images from two similar experiments are shown.
MAVS Regulates Primary and Secondary T Cell Immunity Journal of Virology
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control of WT WNV dissemination and clearance (17). Given the phenotype in Mavs/
mice, we determined the role of type I IFN during WNV NS4B-P38G infection. IFN-/
receptor-deﬁcient (A129) mice and their WT littermate controls were injected intraperi-
toneally (i.p.) with 500 PFU of WNV NS4B-P38G. All A129 mice succumbed to infection
within a week or so, whereas WT controls survived infection 100% without displaying
any clinical signs (Fig. 2A). These results indicate that type I IFN signaling is essential for
host protection against WNV NS4B-P38G infection. We next measured type I IFN levels
in NS4B-P38G-infected WT and Mavs/ mice. Blood IFN- levels were reduced in
Mavs/ mice compared to WT controls on days 1 and 6 p.i. (Fig. 2B), whereas IFN-
levels were diminished in Mavs/mice only on day 6 (Fig. 2C). Splenic type I IFN levels
also were decreased in the Mavs/ group on day 1, but the differences between the
two groups became insigniﬁcant at later time points (Fig. 2D and E). Levels of IFN-
stimulating genes (ISGs), including Oas1a and Iﬁt2, were lower in both the blood (Fig.
2F and G) and spleens (Fig. 2H and I) of Mavs/mice on day 1 but increased to higher
or equivalent levels at later time points. In the CNS, the IFN- and IFN- levels in the
Mavs/ group were either higher or equivalent compared to WT mice on days 4 and
6 p.i., indicating a MAVS-independent induction pathway (Fig. 2J and K).
We next evaluated the effect of MAVS signaling on proinﬂammatory cytokine and
interleukin-10 (IL-10) levels, which correlate with greater viral infection and brain
pathology in WT mice infected with WT-WNV (11, 18, 19). We observed lower levels of
IL-6 and IL-12p40 on days 1, 2, and 3 p.i. with WNV NS4B-P38G in the blood of Mavs/
mice; these levels became insigniﬁcant at later time points (Fig. 3A and B). The
production of other inﬂammatory cytokines, including tumor necrosis factor alpha
(TNF-), IL-1, and IFN-, was not different between these two groups (Table 1). Blood
levels of IL-10 were higher in Mavs/ mice on day 6 p.i. (Table 1). In the CNS,
production of proinﬂammatory cytokines, (IL-1, IL-6, IL-12, and TNF-; Fig. 3C to F) and
chemokines (CCL5, CXCL9, CXCL10, and MCP-1; Fig. 3G to J) were higher in Mavs/
mice on day 6 p.i. Overall, the antiviral innate responses were diminished transiently in
the peripheral tissues of Mavs/ mice, but these responses were either unaffected or
FIG 2 Type I IFN response after WNV NS4B-P38G mutant infection. (A) Survival of WT 129Sv/Ev (WT; n  6) and IFN-/R/ (n  9) mice after an i.p. injection
with 500 PFU of WNV NS4B-P38G. (B to E) Type I IFN expression levels in the blood (B and C) and spleens (D and E) were determined by Q-PCR assay. (F to
I) ISG expression levels in the blood (F and G) and spleens (H and I) as determined by Q-PCR. (J and K) Type I IFN levels in brains of WNV NS4B-P38G-infected
mice determined by Q-PCR. Data are presented as the fold increase compared to the mock-infected animals. The results are representative of three experiments
(n  4 to 8). **, P  0.01; *, P  0.05 (compared to the WT group).
Luo et al. Journal of Virology
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heightened in the CNS, indicating MAVS-independent innate immune responses in the
CNS.
CD4 T cell responses, but not B cell or CD8 T cell responses, were impaired
in NS4B-P38G-vaccinated Mavs/ mice. B-cell-mediated humoral responses are
critical for the host defense against disseminated infection by WT WNV (20). As shown
in Fig. 4A and B, WNV-speciﬁc IgM production was only modestly diminished in the
serum of Mavs/ mice on day 4, but not at later time points. No differences were
noted between the levels of serum IgG of the two groups on days 4, 6, and 7 p.i. Neither
group showed neutralization titers of higher than 20 within the ﬁrst week, and no
differences were detected between them (data not shown). CD4 and CD8 T cells are
important for host survival after WT WNV infection and contribute to long-lasting
protective immunity (21, 22). Compared to WT mice, the number of IFN- CD4 T cells
and IFN- TNF- CD4 T cells were both decreased in Mavs/ mice on day 4 (Fig.
4C to F). No differences were observed for CD8 T cells between the two groups of
mice. On day 7, CD4 T cells of NS4B-P38G-infectedMavs/mice produced 5-fold-less
IFN- upon ex vivo stimulation with WNV-speciﬁc peptides, whereas CD8 T cells in
these mice produced more IFN- than those of WT mice (Fig. 4G). Furthermore, CD4
T cells isolated from WNV NS4B-P38G-infected Mavs/ mice produced less IL-2 than
those of WT mice on days 4 and 7 p.i. (Fig. 4H). CD8 T cells of Mavs/ mice also
produced less IL-2 only on day 7 (Fig. 4H). In summary, CD4 T cells of Mavs/ mice
infected with WNV NS4B-P38G showed consistently lower effector function. To deter-
mine the role of primary CD4 T cells in host protection, naive Mavs/ mice were
reconstituted with CD4 T cells isolated from WT and Mavs/ mice on day 5
postvaccination. Next, reconstituted mice were challenged with 500 PFU of WNV
NS4B-P38G. Mice that received CD4 T cells from NS4B-P38G-vaccinated Mavs/mice
all succumbed to infection, whereas about 65% of Mavs/ mice received CD4 T cells
FIG 3 Inﬂammatory/chemotactic cytokine response after WNV NS4B-P38G mutant infection. Inﬂammatory cytokine and chemokine levels in blood (A and B)
and in brains (C to J) at indicated time points were determined by Q-PCR assay. Data are presented as the fold increase compared to the mock-infected animals.
Data are presented as means  the SEM (n  4 to 8). **, P  0.01; *, P  0.05 (compared to the WT group).
TABLE 1 Serum cytokine levels at days 2 and 6 postinfectiona
Cytokine
Mean cytokine level (pg/ml)  SD
Day 2 Day 6
WT mice Mavs/ mice WT mice Mavs/ mice
IL-1 264.8 71.9 143.6 22.2 591 103 588.4 41.6
TNF- 2,232 886 1,772 343.5 4,230 774 4,212 691
IFN- 39.4 17.9 46.6 15.3 1,364 272.3 1,752 240
IL-10 245.7 78.1 130.4 21.2 140.4 32.7 417.1 49.5†
aBlood was harvested from WNV-infected mice at the indicated time points postinfection. Serum cytokine
levels were measured using a Bio-Plex assay. *, P  0.05; †, P  0.01 (compared to WT group; n  4 to 5).
MAVS Regulates Primary and Secondary T Cell Immunity Journal of Virology
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of NS4B-P38G-vaccinated WT mice survived infection (Fig. 4I). These results further
indicate that CD4 T cells of Mavs/ mice have impaired antiviral responses.
NS4B-P38G triggered lower type I IFN, ISG, and proinﬂammatory responses in
Mavs/ DCs and compromised the antigen-presenting capacity for CD4 T cells.
DCs are antigen-presenting cells (APCs) that initiate T cell responses and are permissive
to WT WNV infection (23). The NS4B-P38G replication was enhanced in Mavs/ DCs
(Fig. 5A and B) and remained high on day 4 p.i. compared to WT DCs, where it was
cleared. Type I IFN levels were reduced on day 1 and/or day 4 in Mavs/ DCs
compared to the WT cells (Fig. 5C and D). Inﬂammatory cytokines, including IL-6 and
IL-12, were also diminished in Mavs/ DCs (Fig. 5E and F), although no differences
were detected in the production of other inﬂammatory cytokines, such as TNF- and
IL-1 (data not shown). In assessing APC functions, we found that the percentage of
CD80 (Fig. 5G) and major histocompatibility complex class II (MHC-II) expression (Fig. 5I)
was lower for DCs isolated from NS4B-P38G-infected Mavs/mice on day 3 compared
to WT controls. No differences were noted on CD86 (Fig. 5H) between the DCs of the
two groups (data not shown). Consistent with these results, using an in vitro T cell
priming assay, we observed that the DCs of Mavs/ mice cocultured with OT-II T cells
produced less IL-2 (Fig. 5J) and showed reduced T cell proliferation (Fig. 5K and L)
compared to WT cells. Taken together, these results indicate that a deﬁciency of MAVS
results in less activation and compromised APC functions in DCs during WNV NS4B-
P38G infection.
To further understand the role of MAVS-mediated innate signaling in DC activation,
we next analyzed the expression of a panel of WNV-inducible genes by Q-PCR array. As
shown in Fig. 6A and B, the levels of many ISGs, including Irf7, Iﬁ44, Isg15, Oas1a, Rsad2,
Iﬁt1, Ifti2, Iﬁ27a, Ddx58, Ccl2, and Cxcl10, were reduced by 1.5-fold in NS4B-P38G-
infected Mavs/ DCs compared to WT cells. In contrast, Irf3, Irf5, Ccl5, and NFkb1 gene
expression levels were slightly increased in NS4B-P38G-infected Mavs/ DCs com-
pared to WT cells. Irf3 and Irf7 are two ISGs important for IFN induction upon WT WNV
infection in myeloid DCs (23, 24). Here, DCs of Irf3/, Irf7/, or Irf3/ Irf7/ mice
displayed a transient reduction of type I IFN expression and enhanced viral replication
on day 1. However, the viral load was reduced in all types of DCs by day 4 (Fig. 6C, D,
and E). These results suggest that IRF3 and IRF7 are transiently involved in the control
FIG 4 Antibody and T cell responses after primary infection with WNV NS4B-P38G. (A and B) Humoral responses during primary WNV NS4B-P38G infection. Sera
were collected from noninfected mice (NF) or from mice infected with WNV NS4B-P38G mutant at days 4, 6, and 7 after primary infection. The development
of WNV-speciﬁc IgM (A) or IgG (B) antibodies was determined by ELISA. (C to F) Splenocytes were harvested at days 0 and 4 after primary WNV NS4B-P38G
infection, cultured ex vivo with WNV peptides for 5 h, and then stained for IFN-, TNF-, and T cell markers. The total numbers of IFN- (C) and IFN- TNF-
(D) T cell subsets per spleen are indicated. (E and F) Representative results from three similar experiments. (G and H) Splenocytes were harvested at days 0,
4, and 7 after primary WNV NS4B-P38G infection and cultured ex vivo with WNV-speciﬁc peptides for 3 days; IFN- and IL-2 production was then measured in
the cell culture supernatant. **, P  0.01; *, P  0.05 (compared to WT mice). n  4 to 5 mice/group pooled from two separate experiments. (I) Survival of naive
Mavs/ mice transferred with CD4 T cells of day 5 vaccinated WT (n  7) or Mavs/ mice (n  7), followed by challenge with 500 PFU of WNV NS4B-P38G.
Luo et al. Journal of Virology
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of NS4B-P38G replication in DCs. Overall, MAVS is required for the induction of type I
IFNs, the control of viral replication, and the activation of myeloid DCs upon WNV
NS4B-P38G infection.
MAVS is not required for host protection and development of WNV-speciﬁc T
cell recall responses upon secondary challenge. To determine the role of MAVS in
long-lasting host immunity, WT and Mavs/ mice were injected i.p. with 50 PFU of
WNV NS4B-P38G mutant. On day 30 p.i., we examined CD4 and CD8 T cell effector
functions in the surviving mice. Upon ex vivo stimulation with WNV-speciﬁc peptides,
there were no differences in the number of IFN- CD4 T cells between the two
groups of mice, whereas Mavs/ mice had 2-fold more IFN- CD8 T cells than WT
mice. Interestingly, the numbers of effector memory CD4 (CD27 CD62L) and CD8
(CD127 CD62L) T cells were enhanced in Mavs/ mice compared to WT mice (Fig.
7A and B). Similar results were observed for splenic CD8 T cell response at 2.5 months
p.i., whereas the splenic CD4 T cells of NS4B-P38G-infected Mavs/ mice produced
more IFN- upon ex vivo stimulation with WNV-speciﬁc peptides (Fig. 7C and D). No
differences were noted in brain T cell responses between these two groups of mice (Fig.
7E and F). Both groups of mice had similar levels of WNV-speciﬁc antibody responses
on day 30 p.i. (Fig. 7G to I). Next, surviving mice from both groups were challenged with
a lethal dose of WT WNV. Remarkably, both WT and Mavs/ mice survived infection
without showing any clinical signs of disease (Fig. 8A). There were no detectable
viremia in either group at day 4 after rechallenge (Fig. 8B and C). However, WNV-
speciﬁc IgM production was lower in Mavs/ mice than in WT mice (Fig. 8D). There
were no differences in IgG response or neutralization titers between the two groups
(Fig. 8E and F). The percentages and numbers of IFN- CD4 T cells and IFN-
TNF- CD4 T cells also were equivalent between the two groups of mice. In contrast,
there was a greater CD8 T cell response in Mavs/ mice compared to WT mice (Fig.
8G to K). IL-2 production from CD4 or CD8 T cells of both groups of mice was similar
(Fig. 8L). To determine the role of CD4 T cell recall response in host protection during
secondary infection, naive Mavs/mice were adoptively transferred with CD4 T cells
FIG 5 WNV NS4B-P38G infection in DCs. WT and Mavs/ DCs were infected with WNV NS4B-P38G. (A and B) The viral load was measured at the indicated time
points by FFA (A) and Q-PCR assay (B). (C to F) Cytokine production was assessed by Q-PCR (C and D) or Bio-Plex assays (E and F). (G to I) CD80, CD86, and
MHC-II expression on DCs isolated from naive or NS4B-P38G-infected mice on day 3 p.i. (J to L) T cell priming assay. CFSE-labeled CD4 T cells from naive OT-II
transgenic mice were cocultured with DCs from WNV-NS4B-P38G mutant-infected WT or Mavs/mice in the presence or absence of the OVA 323-339 peptide.
Cells and supernatant were harvested at day 5 and analyzed for IL-2 production (J) and T cell proliferation (K and L). n  4. *, P  0.05; **, P  0.01 (compared
to the WT group).
MAVS Regulates Primary and Secondary T Cell Immunity Journal of Virology
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isolated from WT or Mavs/ mice on day 30 p.i., followed by infection with 500 PFU
of WNV NS4B-P38G. Similar survival rates were observed between mice transferred with
CD4 T cells from NS4B-P38G-infected WT and Mavs/ mice (Fig. 8M). Overall, these
results suggest that MAVS is not required for host protection during secondary chal-
lenge with WT WNV after priming with the NS4B-P38G mutant. In addition, MAVS
deﬁciency either has no effect or even promotes T cell recall responses during second-
ary challenge.
DISCUSSION
Upon viral infection, activation of multiple PRRs leads to the production of type I
IFNs, proinﬂammatory cytokines, and chemokines. The innate immune products of PRR
signaling are directly involved in viral clearance. More evidence suggests that they also
contribute to activation of adaptive immunity via promoting APC maturation and/or
directly regulating the functions of adaptive immune cells (1–4). In this study, our
results suggest that MAVS is required for host protection during priming with NS4B-
P38G but is not essential for protecting host from secondary infection with a lethal dose
of WT WNV. A deﬁciency of MAVS in NS4B-P38G-vaccinated mice resulted in a tran-
siently reduced production of antiviral cytokines and impaired primary CD4 T cell
activities in peripheral organs. CD4 T cells are known to play a direct role in limiting
viral replication during WT WNV infection (25). We also found that higher viral loads in
the CNS led to the induction of type I IFNs, inﬂammatory cytokines, and chemokines in
a MAVS-independent manner. Thus, the impaired CD4 T cell activities and antiviral
innate responses in the periphery organs contribute to a higher viral load, more virus
FIG 6 ISGs induction following WNV NS4B-P38G infection in BM-DCs. (A and B) PrimePCR array. (A) Clustergram image depicting the relative expression of a
sample. Upregulation (higher expression) is indicated by a red square, downregulation (lower expression) is indicated by a green square, and no regulation is
indicated by a black square. On the outer edges of the data plot is a dendrogram, which indicates the clustering hierarchy. (B) Scatter plot showing the
normalized expression of targets for NS4B-P38G-infected WT versus Mavs/ DCs. The plot image shows the changes in target expression based on the
threshold set of 1.5. Upregulation is indicated by red circles, downregulation is indicated by green circles, and no change is indicated by black circles. (C to
E) WNV NS4B-P38G infection in BM-DCs of WT, Irf3/, Irf7/, and Irf3/ Irf7/ mice. (C and D) Cytokine expression was determined by Q-PCR. (E) Viral load
was measured at the indicated time points by FFA. The results are representative of two experiments (n  5 to 6). **, P  0.01; *, P  0.05 (compared to the
WT group).
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dissemination, and greater inﬂammatory cell inﬁltration into the CNS during priming
with NS4B-P38G. However, NS4B-P38G-vaccinated Mavs/ mice exhibited equivalent
levels of protective CD4 T cell recall response during secondary WT WNV infection.
Type I IFNs and proinﬂammatory cytokines are known to promote DC maturation (26,
27). Here, NS4B-P38G induced lower type I IFNs, IL-6 and IL-12 production in Mavs/
DCs compared to WT DCs, thereby compromising their antigen-presenting capacity.
Furthermore, IL-1, IL-6, and TNF- can act directly on naive T cells to provide a third
signal, to synergize with signals from the TCR and costimulatory receptors, and to
regulate the expansion and survival of CD4 memory T cells (28). We found that MAVS
deﬁciency resulted in a transient reduction of blood IL-6 and IL-12 levels during early
stage of infection with NS4B-P38G but recovered to normal levels at a late stage of
infection. The production of other inﬂammatory cytokines, such as IL-1 and TNF-,
was similar between the two groups. Thus, these results support the observation that
CD4 T cell recall responses were not affected in the absence of MAVS.
Current research on the role of MAVS in adaptive immunity has been focused mainly
on humoral and primary CD8 T cell responses. For example, it was reported that MAVS
deﬁciency dramatically inhibited T-independent antibody responses (29). However, we
only observed a modest decrease on WNV-speciﬁc IgM responses but no changes in
neutralization activity in Mavs/ mice during NS4B-P38G priming and secondary WT
WNV infection. There are contradictory reports about the role of MAVS signaling in
regulating CD8 T cell response. One early report showed that during infection with
hepatitis C virus, another member of the Flaviviridae family, despite the NS3/4A-
mediated cleavage of mouse MAVS, infected murine hepatocytes were eliminated by
hepatic CD8 T cells, indicating unaffected effector functions (30). Two other groups
also demonstrated that MAVS is not required for cytotoxic activities or recruitment of
CD8 T cells into the lungs and airways during respiratory syncytial virus infection (31,
FIG 7 Antibody and T cell responses in WNV NS4B-P38G-infected mice before rechallenge. (A and B) Splenocytes were harvested at day 30 after NS4B-P38G
primingm cultured ex vivo with WNV peptides for 5 h, and stained for IFN-, T cell markers, and CD62L, CD27, or CD127. The total numbers of IFN-, IFN-
CD27 CD62L CD4, or CD8 T cell subsets per spleen are shown. (C to F) Splenocytes (C and D) or brain leukocytes (E and F) isolated from both groups of
mice at 2.5 months p.i. and were cultured ex vivo with WNV peptides for 3 days. IFN- and TNF- production was measured in the cell culture supernatant.
(G to I) Humoral response. Sera were collected from noninfected (NF) or mice infected with WNV NS4B-P38G mutant at day 30 p.i. WNV-speciﬁc IgM (G) or IgG
(H) antibodies were determined by ELISA or neutralization assay (I).
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32). Nevertheless, activation of MAVS signaling induces the production of type I IFNs,
which are the main candidate signal 3 cytokines for CD8 T cells in response to many
intracellular pathogens (1–3, 33, 34). Accordingly, during WT WNV infection, blockade
of type I IFN signaling starting on day 4 was shown to induce dysfunctional CD8 T cell
response with exhaustion phenotypes (35). In this study, we found that type I IFN levels
of NS4B-P38G-vaccinated Mavs/ mice were decreased in serum but maintained at
normal levels in the spleen after day 1. This partial reduction of type I IFN did not seem
to affect CD8 T cell activation in Mavs/ mice. Compared to WT mice, primary CD8
T cells showed normal effector functions in periphery organs and maintained the
capacity to migrate into the CNS within the ﬁrst week postinfection. Furthermore,
Mavs/ mice exhibited stronger CD8 memory T cell activity on day 30 postpriming
and had more robust recall response upon rechallenge with WT WNV infection. It was
reported that the initial viral load correlates with the magnitude of CD8 T cell
responses during immunization with the yellow fever virus vaccine (YFV-17D) (36).
NS4B-P38G-vaccinated Mavs/ mice showed enhanced viral loads and delayed viral
clearance in tissues, which may contribute to a higher magnitude of CD8 T cell recall
responses and a mild increase on the number of CD4 effector memory T cells. In
summary, our study suggests that MAVS is dispensable for the development of memory
CD4 and CD8 T cells in NS4B-P38G-vaccinated mice.
Analogous to our studies with NS4B-P38G, MAVS was previously shown to be
essential for host protection against the pathogenic WT WNV infection (16, 37). MAVS
is important for induction of type I IFNs and control of WT WNV replication in DCs.
MAVS deﬁciency is also associated with increased CNS inﬂammation. However, WT
WNV and NS4B-P38G-infected Mavs/ mice displayed differential innate and adaptive
immune responses. For example, there were elevated systemic type I IFN, proinﬂam-
matory cytokine and chemokine responses, enhanced humoral responses with signif-
icantly reduced neutralization activity, and increased numbers of virus-speciﬁc CD8 T
FIG 8 Antibody and T cell responses in WNV NS4B-P38G-infected mice during secondary challenge. (A) Survival rate. WT (n  15) and Mavs/ (n  16) mice
that survived primary WNV NS4B-P38G mutant infection were rechallenged with lethal WT WNV at day 30. (B and C) Viremia on day 4 after rechallenge (R-D4)
was determined by using a Q-PCR assay (B) or an FFA (C) (n  6 to 8). (D to F) Humoral response during secondary WNV infection. Sera were collected from
noninfected mice (NF) or mice infected with WNV NS4B-P38G mutant at day 4 after rechallenge (R-D4) with WT WNV. WNV-speciﬁc IgM (D) or IgG (E) antibodies
were determined by ELISA or neutralization assay (F). (G to K) Splenocytes were harvested from noninfected (NF) or mice at day 4 after rechallenge with WT
WNV (R-D4), cultured ex vivo with WNV peptides for 5 h, and then stained for IFN-, TNF-, and T cell markers. The percentages and total numbers of IFN-
(G and H) and IFN- TNF- (I and J) T cell subsets per spleen are shown. (K) Representative image of three similar experiments is shown. (L) Splenocytes were
cultured ex vivo with WNV peptides for 3 days, and IL-2 production was measured in the cell culture supernatant. (M) Survival of naive Mavs/mice transferred
with CD4 T cells of day 30 NS4B-P38G-infected WT (n  6) or Mavs/ (n  8) mice, followed by challenge with 500 PFU of WNV NS4B-P38G.
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cells in the periphery of WT WNV-infected Mavs/ mice. Furthermore, there were
equivalent number of CD4 T cells in both groups of mice on day 6 post WT WNV
infection. Previous studies also showed that MAVS-dependent induction of ISGs upon
WT WNV infection can occur through an IRF-5-dependent, yet IRF-3- and IRF-7-
independent pathway (23). Here, we noticed a mild increase on IRF5 expression in
NS4B-P38G-infected Mavs/ DCs compared to WT DCs (Fig. 6). The underlying mech-
anisms of MAVS-induced differential immune responses are not clearly understood.
NS4B protein of ﬂaviviruses has been associated with evasion of host innate immunity
(6–8, 38, 39). In particular, the highly conserved N-terminal domain (amino acids 35 to
60) of NS4B protein bears a resemblance to an immunomodulatory tyrosine inhibitory
motif found in various components of mammalian cell signaling cascades (40), which
is thought to contribute to its antagonist activities for IFN and inﬂammatory cytokine
signaling (7, 8, 38). We have previously shown that NS4B-P38G induces higher innate
and adaptive T cell response than wild-type WNV (10). Thus, it is likely that the P38G
substitution contributes to MAVS-induced differential innate and adaptive immune
responses upon infection with WT WNV and the NS4B-P38G vaccine strain.
Live attenuated vaccines, which induce durable protective immunity, constitute an
important strategy to control ﬂavivirus infections, including yellow fever and Japanese
encephalitis viruses and, more recently, dengue virus. PRR-mediated type I IFNs and
proinﬂammatory cytokines synergize with signals from the T cell and costimulatory
receptors to induce the functional maturation of T cells upon pathogen infection (1–3).
The use of PRR agonists has been a major focus of research in vaccine development
against these viral diseases. For example, activation of the RIG-I pathway promotes T
follicular helper cell induction during inﬂuenza vaccination and protective immunity
(41). Our investigation of the role of PRR-mediated signaling pathways in regulation of
WNV NS4B-P38G mutant induced protective adaptive immunity may provide a model
for the rational development and optimization of other live attenuated ﬂavivirus
vaccines, including ZIKV.
MATERIALS AND METHODS
Mice. Six- to ten-week-old WT C57BL/6 (B6), 129Sv/Ev, and OT-II (B6) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME). Ifnr/ mice in a 129Sv/Ev background or (A129), Mavs/,
Irf3/, Irf7/, Irf3/ Irf7/ mice (all in a B6 background) have been described previously (16, 23) and
were bred in a pathogen-free mouse facility. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health).
All animal experiments were approved by the Animal Care and Use Committee at the University of Texas
Medical Branch. The WNV NS4B-P38G mutant was produced by site-directed mutagenesis and passaged
twice in Vero cells (9). The parental strain WNV NY99, kindly provided by R. Tesh, was passaged once in
Vero cells and twice in C6/36 cells. Mice were inoculated i.p. with 50 or 500 PFU of WNV NS4B-P38G
mutant. In some experiments, mice were rechallenged with a 100% lethal dose (LD100; 2,500 PFU) of WNV
at day 30 after primary infection. Infected mice were monitored twice daily for signs of morbidity.
Infection of cells. Bone marrow (BM)-derived DCs were generated as described previously (23).
Brieﬂy, BM cells were cultured for 6 days in medium supplemented with granulocyte-macrophage
colony-stimulating factor and IL-4 (Peprotech) to generate myeloid DCs. Cells were infected with WNV at
a multiplicity of infection of 0.2, and supernatants and cells were collected at 24 and 96 h p.i. to measure
cytokine production.
Focus-forming assay. Vero cell monolayers were incubated with sample dilutions ﬁrst for 1 h. A
semisolid overlay containing 0.8% methylcellulose (Sigma-Aldrich, St. Louis, MO), 3% fetal bovine serum
(FBS), 1% penicillin-streptomycin, and 1% L-glutamine (Invitrogen) was then added. At 48 h, the semisolid
overlay was removed, cell monolayers were washed with phosphate-buffered saline (PBS), air dried, and
ﬁxed with acetone-methanol (1:1) solution for at least 30 min at 20°C. Cells were incubated with a
rabbit WNV polyclonal antibody (kindly provided by R. Tesh), followed by goat anti-rabbit horseradish
peroxidase-conjugated IgG (KPL, Gaithersburg, MD) at room temperature for 1 h, respectively. Subse-
quently, the cells were incubated with a peroxidase substrate (Vector Laboratories, Burlingame, CA) until
color developed. The number of foci was determined manually and used to calculate viral titers
expressed as FFU/ml. The limit of detection for the assay was determined to be 90 FFU/ml.
Q-PCR and PCR array. WNV-infected samples were resuspended in TRIzol (Invitrogen) for RNA
extraction. Complementary DNA (cDNA) was synthesized using a qScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). The sequences of the primer sets for WNV envelope (WNVE), cytokine, and ISG cDNA and
PCR conditions were as described previously (11, 23, 42, 43). The assay was performed in the CFX96
real-time PCR system (Bio-Rad). Gene expression was calculated either based on CT values by using the
formula 2[CT(target gene)CT(GAPDH)], as described previously (44), or the ratio of the amount of ampliﬁed
gene compared with the amount of -actin cDNA as the relative levels in each sample. A 25-gene
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PrimePCR assay (Bio-Rad) was performed according to the manufacturer’s protocol. Brieﬂy, RNA was
puriﬁed from noninfected and WNV-infected cells by using an RNeasy extraction kit (Qiagen, Valencia,
CA) and quantitated by spectrometry. cDNA was synthesized by using iScript family reverse transcription
kits and then loaded onto 96-well PCR array plates for ampliﬁcation on the CFX96 real-time PCR system
(Bio-Rad). The list of 25 genes was described previously (43). Data analysis was performed by using CFX
manager software.
Brain leukocyte isolation. Brain leukocytes were isolated at day 7 or 2.5 months p.i. based on a
previously described method (45). After extensive cardiac perfusion to deplete intravascular leukocytes,
brains were collected and homogenized. The cell homogenates were centrifuged and resuspended in 7
ml of PBS with 2% FBS mixed with 3 ml of 90% Percoll (Sigma-Aldrich) in PBS. The cell suspension was
placed under 1 ml of 70% Percoll in RPMI 1640 and centrifuged at 800 g for 20 min at 22°C. Leukocytes
at the interface were harvested and counted.
Cytokine Bio-Plex. Tissue culture supernatants or mouse sera were collected for analysis of cytokine
production using a Th17 6-Plex or 23-Plex Bio-Plex Pro mouse cytokine assay (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA). Microtiter plates were coated with recombinant
WNV E protein (45) overnight at 4°C at 50 ng/well. Sera were diluted 1/30 in PBS with 2% bovine serum
albumin, followed by incubation for 1 h at room temperature. Alkaline phosphatase-conjugated goat
anti-mouse IgG or IgM (Sigma-Aldrich) at a dilution of 1/1,000 in PBS-Tween was then added for 1 h.
Color was developed with p-nitrophenyl phosphate (Sigma-Aldrich), and the intensity was determined at
an absorbance of 405 nm using a spectrophotometer.
Plaque reduction neutralization tests (PRNTs). Neutralizing antibody titers were determined using
a 50% neutralization cutoff (PRNT50). Serum was diluted 1:5 in PBS and heat inactivated at 56°C for 30
min before preparing 2-fold dilutions in 100 l of maintenance medium. The parental virus was diluted
to 200 PFU/100 l, and a 100-l portion of virus was added to 100 l of serially diluted serum, mixed,
and placed at 4°C overnight. Then, 100 l of the serum-virus mixture was added to Vero cells in 6-well
plates. The plaques were counted, and the PRNT50 was determined.
Histology. Mice were perfused extensively with PBS. Brains and spleens were removed and placed
in 4% paraformaldehyde (PFA) for 3 days at 4°C, followed by 70% ethanol for 24 h before they were
embedded in optimal cutting temperature compound. Samples were prepared for hematoxylin and
eosin (H&E) staining at the Histopathology Laboratory Core at Baylor College of Medicine (Houston, TX).
Flow cytometry. Splenocytes were stained with antibodies for CD11c, CD80, CD86, CD3, CD4, or CD8
(e-Biosciences, San Diego, CA). Isolated brain leukocytes were stained with antibodies for cell surface
markers, including CD3, CD4, CD8, CD11b, and CD45 (BD Biosciences). After staining, the cells were ﬁxed
with 1% paraformaldehyde in PBS and examined using a C6 ﬂow cytometer (BD Biosciences). Dead cells
were excluded on the basis of forward and side light scatter. Data were analyzed with a CFlow Plus ﬂow
cytometer (BD Biosciences).
Intracellular cytokine staining. Splenocytes were stimulated with WNV-speciﬁc NS3 and E peptides
(RRWCFDGPRTNTILE and PVGRLVTVNPFVSVA, respectively [25]) for CD4 T cells or with WNV-speciﬁc
NS4B and E peptides (SSVWNATTA and IALTFLAV, respectively [46]) for CD8 T cells for 5 h at 37°C in the
presence of Golgi-plug (BD Biosciences). Cells were stained with antibodies for CD3, CD4, or CD8 or in
some experiments with CD27, CD127, and CD62L, ﬁxed in 2% paraformaldehyde, and permeabilized with
0.5% saponin before the addition of anti-IFN-, anti-TNF-, or control rat IgG1 (e-Biosciences). Samples
were processed with a C6 ﬂow cytometer instrument as described above.
In vitro T cell priming assays. CD4 T cells and DCs were puriﬁed from splenocytes of naive OT-II
transgenic mice and WNV-infected mice, respectively, by using anti-CD11c and anti-CD4 magnetic beads
according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). CD4 T cells (2  106 cells)
were labeled with 0.5 mol of CFSE (carboxyﬂuorescein succinimidyl ester; Invitrogen)/liter and mixed with
DCs at a 10:1 ratio, with or without OVA peptide (amino acids 323 to 339 [OVA 323-329], 1 g/ml; GenScript,
Piscataway, NJ) for 5 days. The cells were harvested, and CD4 T cells were analyzed for proliferation based
on CSFE dilution. Supernatant was collected at day 3 for analysis of cytokine production.
Adoptive transfer of CD4 T cells. Single-cell suspensions of CD4 T cells were prepared from
spleens of WNV-infected WT or Mavs/ mice by negative selection using magnetic beads (Miltenyi
Biotec). A total of 5  106 cells were injected intravenously into naive 6-week-old Mavs/ mice 24 h
before infection with 500 PFU of WNV NS4B-P38G. After challenge, the infected mice were monitored
twice daily as described above.
Statistical analysis. Survival curve comparisons were performed using Prism software (GraphPad
Software, San Diego, CA) statistical analysis, which uses the log-rank test (equivalent to the Mantel-
Haenszel test). Values for viral burden, cytokine production, antibody titer, and T cell number experi-
ments were presented as means  the standard errors of the mean (SEM). P values of these experiments
were calculated with a nonpaired Student t test or Mann-Whitney test. Statistical signiﬁcance was
accepted at P  0.05.
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